August 28, 2016 8:52 PM ET

Life Sciences Tools and Services

Company Overview of Cancer Research Technology Limited

Company Overview

Cancer Research Technology Limited develops and commercializes new discoveries in cancer research. The company translates academic research into industry propositions for the benefit of cancer patients. Its services include project development, such as project identification, protecting materials, patent filing, project development, marketing, licensing and partnering, and post-signature management; commercialization, including licensing and spin-outs, collaboration, alliances, and consortia; small molecule drug discovery; clinical development services through clinical development partnerships; imaging and diagnostics research services; and funding services. The company also provides Ximbio,...

Angel Building

407 St John Street

London,  EC1V 4AD

United Kingdom

Founded in 1982


44 20 3469 6300


44 20 3014 8633

Key Executives for Cancer Research Technology Limited

Chief Executive Officer and Director
Chief Operating Officer, Director and Chief Executive of Cancer Research Uk
Head of Medicinal Chemistry
Head of Clinical Partnerships
Head of Functional Pharmacology
Compensation as of Fiscal Year 2016.

Cancer Research Technology Limited Key Developments

IDBS and Cancer Research Technology Collaborates to Streamline Plate Correction

IDBS and Cancer Research Technology have collaborated to streamline plate correction in high throughput screening (HTS). The algorithm, developed by IDBS in response to CRT requirements and soon to be offered to all customers, enables ActivityBase users to correct data within acceptable margins in seconds. It improves data quality and reduces the number of results that would otherwise need to be corrected manually or reworked, resulting in significant time and cost savings. The ActivityBase template enables the automated correction of fifty plates in two seconds, with researchers able to view and store both 'before' and 'after' data. The functionality is compatible with data containing control wells as well as for multiple plate layouts.

Cancer Research Technology, Birmingham University and Alta Innovations Collaborate to Commercialize Cancer Research

Cancer Research Technology (CRT) has signed an agreement with the University of Birmingham and its commercial division Alta Innovations (Alta) to work in collaboration to develop and commercialise the university’s cancer research. The two-year agreement is focused on speeding up commercialisation of the University of Birmingham’s major cancer research into diagnostics, treatments and technologies that can benefit patients. Under the deal, Alta will work in close cooperation with the scientists at the university with an aim to recognise most promising cancer research opportunities. CRT, on the other hand, will use its expertise to commercialise cancer research and its vast network across the pharmaceutical and biotechnology industry in order to identify and translate promising research at the university. CRT will work with Alta and the University of Birmingham’s academics in a bid to promising cancer opportunities, along with the major clinical expertise available and the university’s primary research in areas such as immunology and genomics. The financial benefits received from the research will be shared between CRT and the University of Birmingham. CRT will use its financial returns to invest in Cancer Research UK’s life-saving research, while the University of Birmingham will be used for the benefit of the educational charity.

Ignyta, Inc. and Cancer Research Technology Limited to Terminate the License Agreement

Effective as of April 8, 2016, Ignyta, Inc. and Cancer Research Technology Limited mutually agreed to terminate the License agreement between the company and CRT dated as of January 20, 2014 (the CRT Agreement). The termination of the CRT agreement was due to the company's prior determination to cease all development activities relating to its RXDX-108 program. The parties have agreed to cooperate in an orderly transition of the RXDX-108 program and related information and assets to CRT, including all related intellectual property rights. The company does not expect to incur any material expenses in connection with the termination of the CRT agreement.

Similar Private Companies By Industry

Company Name Region
14M Genomics Ltd Europe
Abcellute Ltd. Europe
Ablatus Therapeutics Limited Europe
Accuro Biologics Ltd. Europe
ActinoPharma Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cancer Research Technology Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at